Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11785308 | 1.00 | HDAC2 (0.48) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15694776 | 0.88 | NPSR1 (0.52) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15694686 | 0.88 | NPSR1 (0.52) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10522417 | 0.85 | KDM4E (0.65) | KDM4EHSD17B10ALDH1A1HPGDNPSR1 | |
| SCHEMBL1294947 | 0.84 | HDAC2 (0.60) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1294945 | 0.84 | HDAC2 (0.60) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7692266 | 0.82 | HDAC2 (0.50) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7692271 | 0.82 | HDAC2 (0.50) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10327138 | 0.82 | HDAC2 (0.64) | HDAC2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13865080 | 0.82 | HDAC2 (0.64) | HDAC2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583963-A1 | Proline analogs as ligands for cannabinoid receptors for the treatment of pain | Purdue Pharma L.P. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8084612-B2 | Proline analogs as ligands for cannabinoid receptors | PURDUE PHARMA L.P. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084612-B2 | Proline analogs as ligands for cannabinoid receptors | PURDUE PHARMA L.P. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009087564-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS FOR THE TREATMENT OF PAIN | PURDUE PHARMA L.P. (DE) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | HDAC2 3363/4885HDAC3 2378/4885HDAC4 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.